B Group, Inc. — 13F Holdings & Portfolio
CIK 2043476 · latest 13F-HR filed 2026-08-14
B Group, Inc. manages $213.0M in 13F-reported U.S. long-equity assets across 19 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are QQQ (17.29%), ADMA (12.82%), PALI (11.20%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position, exited 3, added to 10, and trimmed 2.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE 1101
DALLAS, TX 75201
$213.0M
Long-equity book
19
Distinct positions
2026-06-30
Filed 2026-08-14
+1 / −3 / ↑10 / ↓2
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- NRX PHARMACEUTICALS INC$10.3M +161.9%
- TAYSHA GENE THERAPIES INC$4.2M +52.3%
- PALISADE BIO INC$3.9M +19.4%
- ORUKA THERAPEUTICS INC$3.5M +94.0%
- ULTRAGENYX PHARMACEUTICAL IN$1.7M +59.4%
Exited Positions
- APOGEE THERAPEUTICS INC$631.3K
- SOLENO THERAPEUTICS INC$251.1K
- REPLIMUNE GROUP INC$198.9K
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | INVESCO QQQ TR Put | QQQ | 46090E953 | $36.8M | 17.29% | 50,000 | SH |
| 2 | ADMA BIOLOGICS INC | ADMA | 000899104 | $27.3M | 12.82% | 3,262,542 | SH |
| 3 | PALISADE BIO INC | PALI | 696389402 | $23.9M | 11.20% | 11,414,285 | SH |
| 4 | NRX PHARMACEUTICALS INC | NRXP | 629444209 | $16.7M | 7.86% | 4,091,767 | SH |
| 5 | FAETH THERAPEUTICS INC | FTH | 81728A207 | $15.3M | 7.16% | 610,169 | SH |
| 6 | TAYSHA GENE THERAPIES INC | TSHA | 877619106 | $12.3M | 5.76% | 1,800,556 | SH |
| 7 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $11.1M | 5.22% | 33,237 | SH |
| 8 | CELLECTIS S A | CLLS | 15117K103 | $9.8M | 4.62% | 3,281,501 | SH |
| 9 | ZAI LAB LTD | ZLAB | 98887Q104 | $8.6M | 4.02% | 450,646 | SH |
| 10 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $7.5M | 3.53% | 140,000 | SH |
| 11 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $7.1M | 3.35% | 75,000 | SH |
| 12 | IOVANCE BIOTHERAPEUTICS INC | IOVA | 462260100 | $6.2M | 2.93% | 1,500,000 | SH |
| 13 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $6.2M | 2.92% | 70,000 | SH |
| 14 | AURA BIOSCIENCES INC | AURA | 05153U107 | $5.4M | 2.55% | 764,243 | SH |
| 15 | ASSEMBLY BIOSCIENCES INC | ASMB | 045396207 | $4.8M | 2.27% | 175,706 | SH |
| 16 | BRIGHT MINDS BIOSCIENCES INC | DRUG | 10919W405 | $4.7M | 2.22% | 67,500 | SH |
| 17 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 90400D108 | $4.5M | 2.12% | 135,000 | SH |
| 18 | SIGHT SCIENCES INC | SGHT | 82657M105 | $3.7M | 1.72% | 970,000 | SH |
| 19 | FOGHORN THERAPEUTICS INC | FHTX | 344174107 | $976.0K | 0.46% | 200,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $213.0M | 19 | 0001420506-26-001657 |
| 2026-03-31 | 2026-05-15 | $134.9M | 20 | 0001420506-26-001023 |
| 2025-12-31 | 2026-02-17 | $135.4M | 16 | 0001420506-26-000462 |
| 2025-09-30 | 2025-11-14 | $135.9M | 20 | 0001420506-25-003231 |